Ready to transition to a subscription-free, FDA-approved GLP-1
Some patients may benefit from transitioning to lower doses of GLP-1 medications rather than complete discontinuation, though this approach requires further research to establish optimal dosing strategies
Angkustsiri K, Fussell JJ, Bennett A, Schauer J, Ramirez-Celis A, Hansen RL, Van de Water J (2022) Pilot study of maternal autoantibody related Autism (MAR ASD)
These cell types are the principal cells and the intercalated cells identified as type A (alpha) and type B (beta)
Plan sponsors are currently facing critical decisions regarding GLP-1 medications which require balancing costs, member health benefits, and evolving medication landscapes